Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial

Pierre-Marie Roy, Andrea Penaloza, Olivier Hugli, Frederikus A Klok, Armelle Arnoux, Antoine Elias, Francis Couturaud, Luc-Marie Joly, Raphaëlle Lopez, Laura M Faber, Marie Daoud-Elias, Benjamin Planquette, Jérôme Bokobza, Damien Viglino, Jeannot Schmidt, Henry Juchet, Isabelle Mahe, Frits Mulder, Magali Bartiaux, Rosen Cren, Thomas Moumneh, Isabelle Quere, Nicolas Falvo, Karine Montaclair, Delphine Douillet, Charlotte Steinier, Stephan V Hendriks, Ygal Benhamou, Tali-Anne Szwebel, Gilles Pernod, Nicolas Dublanchet, François-Xavier Lapebie, Nicolas Javaud, Alexandre Ghuysen, Mustapha Sebbane, Gilles Chatellier, Guy Meyer, David Jimenez, Menno V Huisman, Olivier Sanchez, HOME-PE Study Group, Pierre-Marie Roy, Andrea Penaloza, Olivier Hugli, Frederikus A Klok, Armelle Arnoux, Antoine Elias, Francis Couturaud, Luc-Marie Joly, Raphaëlle Lopez, Laura M Faber, Marie Daoud-Elias, Benjamin Planquette, Jérôme Bokobza, Damien Viglino, Jeannot Schmidt, Henry Juchet, Isabelle Mahe, Frits Mulder, Magali Bartiaux, Rosen Cren, Thomas Moumneh, Isabelle Quere, Nicolas Falvo, Karine Montaclair, Delphine Douillet, Charlotte Steinier, Stephan V Hendriks, Ygal Benhamou, Tali-Anne Szwebel, Gilles Pernod, Nicolas Dublanchet, François-Xavier Lapebie, Nicolas Javaud, Alexandre Ghuysen, Mustapha Sebbane, Gilles Chatellier, Guy Meyer, David Jimenez, Menno V Huisman, Olivier Sanchez, HOME-PE Study Group

Abstract

Aims: The aim of this study is to compare the Hestia rule vs. the simplified Pulmonary Embolism Severity Index (sPESI) for triaging patients with acute pulmonary embolism (PE) for home treatment.

Methods and results: Normotensive patients with PE of 26 hospitals from France, Belgium, the Netherlands, and Switzerland were randomized to either triaging with Hestia or sPESI. They were designated for home treatment if the triaging tool was negative and if the physician-in-charge, taking into account the patient's opinion, did not consider that hospitalization was required. The main outcomes were the 30-day composite of recurrent venous thrombo-embolism, major bleeding or all-cause death (non-inferiority analysis with 2.5% absolute risk difference as margin), and the rate of patients discharged home within 24 h after randomization (NCT02811237). From January 2017 through July 2019, 1975 patients were included. In the per-protocol population, the primary outcome occurred in 3.82% (34/891) in the Hestia arm and 3.57% (32/896) in the sPESI arm (P = 0.004 for non-inferiority). In the intention-to-treat population, 38.4% of the Hestia patients (378/984) were treated at home vs. 36.6% (361/986) of the sPESI patients (P = 0.41 for superiority), with a 30-day composite outcome rate of 1.33% (5/375) and 1.11% (4/359), respectively. No recurrent or fatal PE occurred in either home treatment arm.

Conclusions: For triaging PE patients, the strategy based on the Hestia rule and the strategy based on sPESI had similar safety and effectiveness. With either tool complemented by the overruling of the physician-in-charge, more than a third of patients were treated at home with a low incidence of complications.

Keywords: Clinical decision-making; Emergency department; Home treatment; Pulmonary embolism; Randomized controlled trial; Risk assessment.

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8408662/bin/ehab373f3.jpg
The international randomized HOME-PE study demonstrates that, for triaging patients with acute pulmonary embolism for home treatment, the Hestia rule and the simplified Pulmonary Embolism Severity Index, complemented by the physician's overruling, are equally safe and efficient.
Figure 1
Figure 1
Enrolment, randomization, and follow-up. Among randomized patients, three subsequently withdrew consent in the Hestia arm and one in the sPESI arm; 77 patients were excluded from the per-protocol population in the Hestia arm: 13 for disregard of the inclusion or exclusion criteria (for 6 patients the initial diagnosis of acute pulmonary embolism was subsequently refuted, 2 patients had systolic blood pressure 48 h, and 3 patients had a time interval between pulmonary embolism diagnosis and inclusion >24 h), 63 for disregard of the protocol strategy (32 were designated for home treatment but discharged home more than 24 h after randomization and 31 were designated for hospitalization but discharged within 24 h following randomization), and 1 for both protocol deviations (unconfirmed pulmonary embolism diagnosis and designated for hospitalization but discharged within 24 h following randomization); 85 patients were excluded from the per-protocol population in the sPESI arm: 18 for disregard of the inclusion or exclusion criteria (for 12 patients, the initial diagnosis of acute pulmonary embolism was subsequently refuted, 3 had a time interval between emergency department presentation and inclusion >48 h, and 3 patients had a time interval between pulmonary embolism diagnosis and inclusion >24 h), 64 for disregard of the protocol strategy (31 were designated for home treatment but discharged home more than 24 h after randomization and 33 were designated for hospitalization but discharged within 24 h following randomization), and 3 for both protocol deviations (2 with unconfirmed pulmonary embolism diagnosis and designated for hospitalization but discharged within 24 h following randomization, and 1 with a time interval between emergency department presentation and inclusion >48 h, and designated for home treatment but discharged home more than 24 h after randomization).
Figure 2
Figure 2
Selection for home treatment. The selection for home treatment included three steps. Step 1: Qualification for home treatment according to the allocated triaging tool. Patients randomized to the Hestia arm qualified for home treatment if all answers were negative. Patients randomized to the sPESI arm qualified for home treatment if the sPESI was 0 points. Step 2: Designation for home treatment according to the physician-in-charge. In both study arms, for designation for home treatment and as per-protocol, the physician-in-charge could overrule the qualification issued from the allocated triaging tool in case of imperative medical or social reasons, or patient’s refusal. The reasons are mentioned in the lateral boxes. Step 3: Final management. Patients were considered to have been treated at home if they were actually discharged within 24 h following randomization, calculated from the patients’ administrative report forms. Protocol deviations were defined as patients designated for home treatment who were discharged after the 24-h limit, or vice versa, as patients designated for hospitalization who were discharged before the 24-h limit. DOAC, direct oral anticoagulant; LMWH, low molecular weight heparin.

References

    1. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jimenez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ni Ainle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020;41:543–603.
    1. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016;149:315–352.
    1. Maughan BC, Frueh L, McDonagh MS, Casciere B, Kline JA. Outpatient treatment of low-risk pulmonary embolism in the era of direct oral anticoagulants: a systematic review. Acad Emerg Med 2021;28:226–239.
    1. Vinson DR, Aujesky D, Geersing GJ, Roy PM. Comprehensive outpatient management of low-risk pulmonary embolism: can primary care do this? A narrative review. Perm J 2020;24:19.163.
    1. Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, Roy PM, Fine MJ. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005;172:1041–1046.
    1. Jimenez D, Aujesky D, Moores L, Gomez V, Lobo JL, Uresandi F, Otero R, Monreal M, Muriel A, Yusen RD, Investigators R. Simplification of the Pulmonary Embolism Severity Index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010;170:1383–1389.
    1. Zondag W, Mos IC, Creemers-Schild D, Hoogerbrugge AD, Dekkers OM, Dolsma J, Eijsvogel M, Faber LM, Hofstee HM, Hovens MM, Jonkers GJ, van Kralingen KW, Kruip MJ, Vlasveld T, de Vreede MJ, Huisman MV; on behalf of the Hestia Study Investigators. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011;9:1500–1507.
    1. den Exter PL, Zondag W, Klok FA, Brouwer RE, Dolsma J, Eijsvogel M, Faber LM, van Gerwen M, Grootenboers MJ, Heller-Baan R, Hovens MM, Jonkers GJ, van Kralingen KW, Melissant CF, Peltenburg H, Post JP, van de Ree MA, Vlasveld LT, de Vreede MJ, Huisman MV; Vesta Study Investigators. Efficacy and safety of outpatient treatment based on the Hestia clinical decision rule with or without N-terminal pro-brain natriuretic peptide testing in patients with acute pulmonary embolism. A randomized clinical trial. Am J Respir Crit Care Med 2016;194:998–1006.
    1. Hendriks SV, Bavalia R, van Bemmel T, Bistervels IM, Eijsvogel M, Faber LM, Fogteloo J, Hofstee HMA, van der Hulle T, Iglesias Del Sol A, Kruip M, Mairuhu ATA, Middeldorp S, Nijkeuter M, Huisman MV, Klok FA; YEARS Investigators. Current practice patterns of outpatient management of acute pulmonary embolism: a post-hoc analysis of the YEARS study. Thromb Res 2020;193:60–65.
    1. Roy PM, Moumneh T, Penaloza A, Sanchez O. Outpatient management of pulmonary embolism. Thromb Res 2017;155:92–100.
    1. Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M, Renaud B, Verhamme P, Stone RA, Legall C, Sanchez O, Pugh NA, N'Gako A, Cornuz J, Hugli O, Beer HJ, Perrier A, Fine MJ, Yealy DM. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011;378:41–48.
    1. Vinson DR, Mark DG, Chettipally UK, Huang J, Rauchwerger AS, Reed ME, Lin JS, Kene MV, Wang DH, Sax DR, Pleshakov TS, McLachlan ID, Yamin CK, Elms AR, Iskin HR, Vemula R, Yealy DM, Ballard DW; eSPEED Investigators of the KP CRESR Network. Increasing safe outpatient management of emergency department patients with pulmonary embolism: a controlled pragmatic trial. Ann Intern Med 2018;169:855–865.
    1. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk NA, Zamorano JL, Zompatori M; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014;35:3033–3069, 3069a–3069k.
    1. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692–694.
    1. Ge M, Durham LK, Meyer RD, Xie W, Thomas N. Covariate-adjusted difference in proportions from clinical trials using logistic regression and weighted risk differences. Drug Inf J 2011;45:481–493.
    1. Nijkeuter M, Sohne M, Tick LW, Kamphuisen PW, Kramer MH, Laterveer L, van Houten AA, Kruip MJ, Leebeek FW, Buller HR, Huisman MV; Christopher Study Investigators. The natural course of hemodynamically stable pulmonary embolism: clinical outcome and risk factors in a large prospective cohort study. Chest 2007;131:517–523.
    1. Bova C, Sanchez O, Prandoni P, Lankeit M, Konstantinides S, Vanni S, Jimenez D. Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. Eur Respir J 2014;44:694–703.
    1. Zondag W, den Exter PL, Crobach MJ, Dolsma A, Donker ML, Eijsvogel M, Faber LM, Hofstee HM, Kaasjager KA, Kruip MJ, Labots G, Melissant CF, Sikkens MS, Huisman MV; Hestia Study Investigators. Comparison of two methods for selection of out of hospital treatment in patients with acute pulmonary embolism. Thromb Haemost 2013;109:47–52.
    1. Quezada CA, Bikdeli B, Villen T, Barrios D, Mercedes E, Leon F, Chiluiza D, Barbero E, Yusen RD, Jimenez D. Accuracy and interobserver reliability of the simplified Pulmonary Embolism Severity Index versus the Hestia criteria for patients with pulmonary embolism. Acad Emerg Med 2019;26:394–401.
    1. Barco S, Mahmoudpour SH, Valerio L, Klok FA, Munzel T, Middeldorp S, Ageno W, Cohen AT, Hunt BJ, Konstantinides SV. Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database. Lancet Respir Med 2020;8:277–287.
    1. Jimenez D, Bikdeli B, Quezada A, Muriel A, Lobo JL, de Miguel-Diez J, Jara-Palomares L, Ruiz-Artacho P, Yusen RD, Monreal M; RIETE Investigators. Hospital volume and outcomes for acute pulmonary embolism: multinational population based cohort study. BMJ 2019;366:l4416.
    1. Beam DM, Kahler ZP, Kline JA. Immediate discharge and home treatment with rivaroxaban of low-risk venous thromboembolism diagnosed in two U.S. emergency departments: a one-year preplanned analysis. Acad Emerg Med 2015;22:788–795.
    1. Wells P, Peacock WF, Fermann GJ, Coleman CI, Wang L, Baser O, Schein J, Crivera C. The value of sPESI for risk stratification in patients with pulmonary embolism. J Thromb Thrombolysis 2019;48:149–157.
    1. Ford I, Norrie J. Pragmatic trials. N Engl J Med 2016;375:454–463.
    1. Barco S, Schmidtmann I, Ageno W, Bauersachs RM, Becattini C, Bernardi E, Beyer-Westendorf J, Bonacchini L, Brachmann J, Christ M, Czihal M, Duerschmied D, Empen K, Espinola-Klein C, Ficker JH, Fonseca C, Genth-Zotz S, Jimenez D, Harjola VP, Held M, Iogna PL, Lange TJ, Manolis A, Meyer A, Mustonen P, Rauch-Kroehnert U, Ruiz-Artacho P, Schellong S, Schwaiblmair M, Stahrenberg R, Westerweel PE, Wild PS, Konstantinides SV, Lankeit M; HoT-PE Investigators. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. Eur Heart J 2020;41:509–518.
    1. Kabrhel C, Rosovsky R, Baugh C, Connors J, White B, Giordano N, Torrey J, Deadmon E, Parry BA, Hagan S, Zheng H. Multicenter implementation of a novel management protocol increases the outpatient treatment of pulmonary embolism and deep vein thrombosis. Acad Emerg Med 2019;26:657–669.
    1. Klok FA, Barco S. Optimal management of hormonal contraceptives after an episode of venous thromboembolism. Thromb Res 2019;181:S1–S5.
    1. Barco S, Mahmoudpour SH, Planquette B, Sanchez O, Konstantinides SV, Meyer G. Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis. Eur Heart J 2019;40:902–910.
    1. Hendriks SV, Klok FA, den Exter PL, Eijsvogel M, Faber LM, Hofstee HMA, Iglesias Del Sol A, Kroft LJM, Mairuhu ATA, Huisman MV. Right ventricle-to-left ventricle diameter ratio measurement seems to have no role in low-risk patients with pulmonary embolism treated at home triaged by Hestia criteria. Am J Respir Crit Care Med 2020;202:138–141.
    1. Delluc A, Tromeur C, Le Ven F, Gouillou M, Paleiron N, Bressollette L, Nonent M, Salaun PY, Lacut K, Leroyer C, Le Gal G, Couturaud F, Mottier D; EPIGETBO Study Group. Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France. Thromb Haemost 2016;116:967–974.
    1. Stein PD, Matta F, Hughes MJ. National trends in home treatment of acute pulmonary embolism. Clin Appl Thromb Hemost 2018;24:115–121.
    1. Roy PM, Corsi DJ, Carrier M, Theogene A, de Wit C, Dennie C, Le Gal G, Delluc A, Moumneh T, Rodger M, Wells P, Gandara E. Net clinical benefit of hospitalization versus outpatient management of patients with acute pulmonary embolism. J Thromb Haemost 2017;15:685–694.
    1. Kovacs MJ, Hawel JD, Rekman JF, Lazo-Langner A. Ambulatory management of pulmonary embolism: a pragmatic evaluation. J Thromb Haemost 2010;8:2406–2411.

Source: PubMed

3
Sottoscrivi